Cue Biopharma, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cue Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Cue Biopharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$8.82M, a 22.8% increase year-over-year.
  • Cue Biopharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$45.7M, a 14.1% increase year-over-year.
  • Cue Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$52.1M, a 2.02% increase from 2022.
  • Cue Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$53.2M, a 21.8% decline from 2021.
  • Cue Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$43.7M, a 2.95% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$45.7M -$8.82M +$2.6M +22.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$48.3M -$10.4M +$3.13M +23.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$51.4M -$12.7M +$712K +5.32% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$52.1M -$13.8M +$1.03M +6.95% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$53.2M -$11.4M -$388K -3.52% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$52.8M -$13.5M -$427K -3.26% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$52.4M -$13.4M +$858K +6.03% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$53.2M -$14.9M -$6.99M -88.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$46.2M -$11M +$1.99M +15.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$48.2M -$13.1M -$2.79M -27.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$45.4M -$14.2M -$1.72M -13.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$43.7M -$7.87M +$3.1M +28.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-21
Q3 2021 -$46.8M -$13M -$2.89M -28.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$43.9M -$10.3M +$639K +5.84% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$44.6M -$12.5M +$477K +3.67% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$45M -$11M -$1.96M -21.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 -$43.1M -$10.1M -$3.04M -42.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$40M -$10.9M -$1.71M -18.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$38.3M -$13M -$1.57M -13.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$36.8M -$9.02M +$1.93M +17.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$38.7M -$7.09M +$5.67M +44.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$44.4M -$9.23M -$1.76M -23.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$42.6M -$11.4M -$3.91M -51.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$38.7M -$10.9M -$505K -4.84% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$38.2M -$12.8M -$7.73M -154% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$30.5M -$7.47M -$3.06M -69.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$27.4M -$7.52M -$4.17M -125% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$23.2M -$10.4M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$5.03M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$4.41M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$3.35M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.